摘要
The study investigated pretreatment Epstein-Barr virus (EBV) DNA status and its prognostic values in 96 patients newly diagnosed Hodgkin lymphoma (HL). With 13.5 % patients in positive EBV DNA status before therapy, the positive group had inferior progression-free survival (PFS) (P = 0.023) as well as overall survival (OS) (P = 0.001). Pretreatment EBV DNA positivity was observed as an independent prognostic factor in OS (P = 0.036) while a trend to predict PFS (P = 0.064). By monitoring changes of EBV DNA copies in 13 patients with positive pretreatment EBV DNA status, 5 of 6 patients with complete response (CR) had their copies undetectable after 3 cycles of first-line treatment and 7 patients with progressive disease (PD) all had elevated EBV DNA copies during their relapsed period. Whole blood EBV DNA may be an adjunctive biomarker to reflect treatment response, risk of disease relapse as well as prognosis in HL patients.
学科与关键词
- Prospective evaluation of blood Epstein–Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomasLupo Julien; Germi Raphaële; Lancar Rémi; Algarte Genin Michèle; Hendel Chavez Houria; Taoufik Yassine; Mounier Nicolas; Partisani Marialuisa; Bonnet Fabrice; Meyohas Marie Caroline; Marchou Bruno; Filippova Anastasiia; Prevot Sophie; Costagliola Dominique; Morand Patrice; Besson CarolineAIDS, 2021, (6).
- 血浆EB病毒DNA在弥漫大B细胞淋巴瘤中的预后意义安娜; 谢亚萍; 徐颖; 施鹏飞; 钱申贤中华内科杂志, 2017, 56(11).
- EBV-DNA拷贝数在EBV~+淋巴瘤患者中的临床意义邱立华; 李越洋; 郑雅心; 袁田; 丁洒; 钱正子; 李兰芳; 冯玉梅; 张会来; 田晨*中国实验血液学杂志, 2021, 29(06): EBV-中国知网.
